Efficiency and safety of the latanoprost and dorzolamide fixed combination in primary open-angle glaucoma initial hypotensive treatment

Purpose: to study the efficacy and safety of latanoprost/dorzolamide fixed combination Dorzoprost in primary open-angle glaucoma (POAG) as initial hypotensive treatment. Material and methods. An observational study included 30 patients (33 eyes) with moderate and advanced POAG with elevated IOP without hypotensive treatment. At the screening Dorzoprost was prescribed as a single evening instillation. The endpoints were IOP, visual acuity, MD, PSD, retinal nerve fiber layer thickness, minimal width of the neuroretinal rim, macula retinal nerve fiber layer thickness, and adverse events. The observation period was 12 weeks. IOP was measured at 1, 4 and 12 weeks. Results. After 1 week, there was a statistically significant decrease in IOP, which remained stable at 12 weeks. The average IOP decrease was 33%. Positive insufficient dynamics of visual acuity, static perimetry and optical coherence tomography parameters was registered. By the end of the observation period, in 9 cases, the appearance of mild conjunctival hyperemia was noted without an increase in the severity of signs of the “dry eye” syndrome. Conclusion. Dorzoprost demonstrated a significant hypotensive effect during initial therapy, a good safety and tolerability profile.